Wave Life Sciences (WVE) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to earnings of $0.17 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -8.26%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.3 per share when it actually produced a loss of $0.32, delivering a surprise of -6.67%.Over the last four quarters, th ...

Group 1 - Vera Therapeutics (NASDAQ:VERA) is identified as one of the 17 biotechnology stocks with more than 50% upside potential, with a price target of $96 set by JPMorgan, indicating an upside of over 127% from current levels [1][3] - Cantor Fitzgerald also maintains an Overweight rating on Vera Therapeutics, with a target price of $100, suggesting nearly 137% upside potential, highlighting favorable conditions for the approval of atacicept for treating IgA-related kidney disorder [4] - The company is a late-stage clinical biotechnology firm focused on immunological conditions, developing treatments for serious diseases, including immunoglobulin A nephropathy and MAU868, a monoclonal antibody for BK viremia infections in transplant patients [5] Group 2 - Anupam Rama from JPMorgan anticipates that as competitors' clinical data becomes available, Vera Therapeutics' stock price could rise towards a more appropriate risk-adjusted valuation [3] - The company is positioned for a successful market entry once it obtains regulatory approvals, indicating strong opportunities for growth [4]

Arquitos Capital Partners, an investment management firm, released its Q4 2025 investor letter. A copy of the letter can be downloaded here. Arquitos Capital Management reported a standout year in which the fund returned 82.1% net of fees in 2025, significantly outperforming the Russell 2000’s 12.8% gain. The manager noted that market conditions became increasingly selective, with capital favoring established, cash-generating businesses while smaller and less liquid growth names faced volatility, particular ...

Core Viewpoint - Investors in the Medical - Biomedical and Genetics sector should consider Exelixis (EXEL) and Liquidia Corporation (LQDA) for potential value opportunities [1] Group 1: Company Rankings - Exelixis has a Zacks Rank of 1 (Strong Buy), while Liquidia Corporation has a Zacks Rank of 2 (Buy) [3] - EXEL has likely seen a stronger improvement in its earnings outlook compared to LQDA [3] Group 2: Valuation Metrics - EXEL has a forward P/E ratio of 12.65, whereas LQDA has a significantly higher forward P/E of 62.04 [5] - EXEL's PEG ratio is 0.65, indicating better value relative to its expected earnings growth compared to LQDA's PEG ratio of 1.13 [5] - EXEL's P/B ratio is 5.33, in contrast to LQDA's P/B ratio of 158.47, suggesting a more favorable valuation for EXEL [6] Group 3: Value Grades - Based on various valuation metrics, EXEL holds a Value grade of B, while LQDA has a Value grade of D [6] - EXEL stands out in both Zacks Rank and Style Scores models, making it a more attractive option for value investors [6]

Performance Overview - Laughing Water Capital ("LWC") achieved a return of approximately 6.8% in Q4, resulting in a full-year return of about 3.9% after fees and expenses, compared to the SP500TR and R2000 which returned approximately 2.7% and 2.2% respectively in the same quarter [3] - Since inception, LWC's cumulative return is approximately 400%, outperforming the SP500TR's ~332% and the R2000's ~175% [4] Investment Philosophy - The company emphasizes investing in off-the-beaten-path businesses led by capable management, particularly during periods of uncertainty, believing this approach can yield outsized returns over time [6][8] - Despite the current market enthusiasm for sectors like artificial intelligence and technology, the company remains focused on fundamental business performance rather than market trends [7][8] Market Dynamics - Recent market trends have favored larger, growth-oriented companies, with a significant outperformance of large-cap stocks over small-cap stocks [10][15] - The SP500 has outperformed the equal-weight SP500 by 34% over the past three years, indicating a strong preference for larger companies [15] Specific Investments - Lifecore Biomedical is highlighted as a key investment, with expectations of significant growth due to its competitive advantages and increasing capacity utilization [13][14] - Liquidia Corp has seen early sales success with its drug Yutrephia, which has outperformed expectations, despite ongoing patent litigation with United Therapeutics [30][31] - NextNav Inc is positioned as a potential leader in providing a terrestrial backup to GPS, with bipartisan support for its proposal to repurpose spectrum for 5G use [36][39] Future Outlook - The company anticipates continued improvement in the fundamental performance of its investments, suggesting that over time, market recognition of these fundamentals will lead to better stock performance [62] - Management remains optimistic about the potential for significant upside in investments like Lifecore and Liquidia, while also acknowledging the challenges posed by market sentiment and timing [29][33]

Core Insights - U.S. stocks experienced an upward trend, with the Dow Jones index increasing by approximately 200 points on Friday [1] Company Highlights - CG Oncology Inc (NASDAQ:CGON) saw its shares rise by 21.8% to $51.05 after announcing an expedited timeline for topline data from the Phase 3 PIVOT-006 clinical trial, now expected in the first half of 2026 [1][2] - Rich Sparkle Holdings Ltd (NASDAQ:ANPA) surged 113.6% to $51.70 following a $39 million offering of 3 million ordinary shares at $13 per share [3] - NovaBay Pharmaceuticals Inc (NYSE:NBY) increased by 34.4% to $12.81 [3] - Quanterix Corp (NASDAQ:QTRX) gained 29.3% to $8.42 after naming Everett Cunningham as President and CEO, effective January 19 [3] - MoonLake Immunotherapeutics (NASDAQ:MLTX) rose 21.7% to $17.45 after receiving FDA feedback on its clinical evidence strategy for Sonelokimab in Hidradenitis Suppurativa [3] - Enliven Therapeutics Inc (NASDAQ:ELVN) increased by 21.5% to $28.24, sharing positive initial data from its Phase 1b ENABLE trial for ELVN-001 in chronic myeloid leukemia [3] - Aeva Technologies Inc (NASDAQ:AEVA) surged 21.2% to $20.47 [3] - Loandepot Inc (NYSE:LDI) rose 20.1% to $2.93 [3] - ASP Isotopes Inc (NASDAQ:ASPI) increased by 19.7% to $7.71 [3] - Allogene Therapeutics Inc (NASDAQ:ALLO) gained 19.5% to $1.78 [3] - Opendoor Technologies Inc (NASDAQ:OPEN) rose 19.2% to $7.67 following a new housing market proposal by President Donald Trump [3] - Liquidia Corp (NASDAQ:LQDA) jumped 14% to $36.22 after announcing preliminary full-year 2025 YUTREPIA net sales [3] - Vistra Corp (NYSE:VST) gained 13.1% to $170.34 after entering into 20-year power purchase agreements for zero-carbon nuclear energy to support Meta's operations [3] - Oklo Inc (NYSE:OKLO) rose 12.6% to $109.95 after announcing an agreement with Meta for a 1.2 gigawatt power campus [3] - Applied Digital Corp (NASDAQ:APLD) surged 11.8% to $35.72, reporting strong second-quarter results and advanced talks with a new hyperscaler tenant [3] - AST SpaceMobile Inc (NASDAQ:ASTS) gained 10% to $99.65 [3] - SanDisk Corp (NASDAQ:SNDK) increased by 9.6% to $366.93 [3] - Mirion Technologies Inc (NYSE:MIR) rose 9.5% to $26.56 [3] - TTM Technologies Inc (NASDAQ:TTMI) gained 9.1% to $72.94 [3] - SoundHound AI Inc (NASDAQ:SOUN) rose 8.5% to $11.96 [3] - Kratos Defense & Security Solutions Inc (NASDAQ:KTOS) gained 8.3% to $112.64, with B. Riley Securities maintaining a Buy rating and raising the price target from $105 to $128 [3]

Core Viewpoint - Investors are evaluating the value opportunities presented by Harmony Biosciences Holdings, Inc. (HRMY) and Liquidia Corporation (LQDA) in the Medical - Biomedical and Genetics sector [1] Group 1: Zacks Rank and Earnings Estimates - HRMY has a Zacks Rank of 2 (Buy), indicating a more favorable earnings estimate revision trend compared to LQDA, which has a Zacks Rank of 3 (Hold) [3] - The stronger earnings estimate revision activity for HRMY suggests an improving analyst outlook, making it a more attractive option for investors [3] Group 2: Valuation Metrics - HRMY has a forward P/E ratio of 10.09, significantly lower than LQDA's forward P/E of 37.43, indicating that HRMY may be undervalued [5] - The PEG ratio for HRMY is 0.39, while LQDA's PEG ratio is 1.03, suggesting that HRMY offers better value relative to its expected earnings growth [5] - HRMY's P/B ratio is 2.59, contrasting sharply with LQDA's P/B of 122.26, further highlighting HRMY's relative undervaluation [6] Group 3: Value Grades - HRMY has been assigned a Value grade of A, while LQDA has a Value grade of D, indicating that HRMY is viewed more favorably by value investors [6] - The combination of Zacks Rank and Style Scores indicates that HRMY is the better investment option compared to LQDA at this time [6]

Company Overview - Intelligent Bio Solutions Inc. (NASDAQ:INBS) announced plans to raise $10 million through a private placement, leading to a significant drop in its share price [1] - Following the announcement, shares of Intelligent Bio fell 19.7% to $7.65 [1] Stock Movements - Lavoro Limited (NASDAQ:LVRO) saw a substantial increase of 181%, reaching $1.2900 [4] - Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) rose 57.7% to $5.32 after issuing FY26 guidance, expecting US net sales of Linzess to be between $1.125 billion and $1.175 billion [4] - Brand Engagement Network, Inc. (NASDAQ:BNAI) jumped 56% to $3.6290 after entering a Vendor Services Project Agreement with a global advertising agency [4] - ChowChow Cloud International Holdings Limited (NYSE:CHOW) increased by 39.7% to $0.8500 due to year-over-year revenue and net income growth in H1 2025 [4] - Sidus Space, Inc. (NASDAQ:SIDU) gained 29% to $4.0314, marking a 470% surge over the past month [4] - Baidu, Inc. (NASDAQ:BIDU) rose 12.1% to $146.57 after announcing a proposed spin-off and Hong Kong listing of its AI unit [4] Declines - Outlook Therapeutics, Inc. (NASDAQ:OTLK) experienced a significant decline of 58% to $0.6632 after receiving a complete response letter from the FDA regarding its biologics license application [4] - ESH Acquisition Corp. (NASDAQ:ESHA) fell 23.5% to $14.68 [4] - Nuvve Holding Corp. (NASDAQ:NVVE) declined 15.3% to $2.1500 after announcing the closing of a private placement [4]

Core Insights - Arquitos Capital Management achieved a net return of 29.6% in Q3 2025, resulting in year-to-date gains of 66.8% [1] - The firm focuses on a select group of companies and is willing to hold investments for many years to realize their value [1] Company Highlights - Liquidia Corporation (NASDAQ:LQDA) is a biopharmaceutical company that addresses unmet patient needs in the U.S. [2] - Liquidia's stock experienced a one-month return of 21.31% and a remarkable 196.82% increase over the past 52 weeks [2] - As of December 10, 2025, Liquidia's stock closed at $32.68, with a market capitalization of $2.843 billion [2] Investment Strategy - Arquitos Capital Management's exposure to Liquidia Corporation is primarily through long-dated call options, indicating strong conviction in the company's long-term potential [3] - Liquidia's share price rose from $11.76 at the beginning of the year to $22.74 at the end of Q3 2025 [3]

Fund Performance - The Summers Value Fund LP achieved a net return of 20.4% in Q3 2025, outperforming the Russell 2000 Index ETF (12.4%) and the Russell 2000 Value Index ETF (12.5%) [2] - Year-to-date, the Fund is up 4.9%, lagging behind the IWM (10.3%) and IWN (8.9%) [2] - Since inception, the Fund has delivered a 12.2% annualized net return compared to 6.8% for IWM and 6.1% for IWN [2][3] Healthcare Sector Overview - The healthcare sector has faced challenges leading to underperformance against broader indexes, influenced by regulatory uncertainty from new FDA leadership and budget pressures at federal agencies [4] - Investors withdrew approximately $13 billion from healthcare funds in 2025, indicating a record annual outflow, while large-cap stocks saw $224 billion in inflows [5] - Despite negative sentiment, the healthcare sector is viewed as defensive and growing, with potential for disciplined investors to find opportunities [5][6] Investment Opportunities - The Fund has increased exposure to biopharma stocks, anticipating outperformance due to an innovation cycle and potential acquisitions by large-cap companies [6] - Notable contributors to the Fund's performance in Q3 included Zimvie (124% acquisition premium), Liquidia (strong sales of Yutrepia), and Consensus Cloud Solutions (return to positive revenue growth) [7] - The Fund initiated a position in uniQure following promising Phase 3 results for its gene therapy drug, which showed a 75% reduction in disease progression [9] Position Updates - Journey Medical, with a market cap of $175 million, launched Emrosi for rosacea treatment, with annualized sales approaching $30 million and potential peak sales exceeding $100 million [12] - Ligand Pharmaceuticals, valued at $3.7 billion, operates as a royalty aggregator and is expected to see strong performance from its drugs Ohtuvaryre and Filspari, with blockbuster potential [13][14] - The Fund's top five holdings include Electromed, Consensus Cloud Solutions, Liquidia, Spok Holdings, and Ligand Pharmaceuticals, with a significant allocation to pharmaceutical and biotechnology stocks [10]